Firefly Neuroscience has developed an innovative technology known as Brain Network Analytics (BNA™), which aims to revolutionize brain health assessments through objective, AI-driven evaluations. BNA™ utilizes a proprietary database of over 77,000 EEG scans from individuals with various cognitive disorders, enabling the early detection of subtle neurological deviations. By employing advanced artificial intelligence and machine learning algorithms, BNA™ analyzes electroencephalogram (EEG) data collected during both resting states and specific brain activities. This comprehensive analysis allows healthcare professionals to identify deviations from normative data, facilitating personalized treatment plans that enhance patient outcomes and operational efficiency.

The BNA™ technology integrates seamlessly into clinical workflows, providing clinicians with intuitive data visualization tools and cloud-based reports that support informed decision-making. By offering objective insights into brain function, BNA™ empowers healthcare providers to tailor interventions based on each patient's unique neurophysiological profile. This capability not only improves diagnostic accuracy but also enhances the overall quality of care, making BNA™ a transformative tool in the management of various neurological and psychiatric conditions. As a result, Firefly Neuroscience positions itself at the forefront of medical technology innovation, with significant potential for market growth and improved healthcare outcomes.

United States

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

Firefly Neuroscience

Company Details